Skaana Management’s Inovio Pharmaceuticals INO Stock Holding History

Skaana Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-400	Closed	-$7.49K	–	176
2022 Q4	$7.49K	Buy	+400	New	+$9.07K	﹤0.01%	141
2022 Q1	–	Sell	-17,192	Closed	-$1.03M	–	163
2021 Q4	$1.03M	Buy	+17,192	New	+$1.38M	0.16%	71

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Skaana Management's INO Position: Q2 2022 in Review

Skaana Management sold out of Inovio Pharmaceuticals (INO) in Q2 2022, closing a stake of 1,779 shares — an estimated $77K sold.

Skaana Management first reported a position in INO in Q4 2021 and held it in 2 quarters. The position peaked at $1.14M in Q4 2021. 184 funds tracked by Wall St. Rank hold INO as of Q2 2022.

Skaana Management reported no remaining Inovio Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Skaana Management sold 1,779 Inovio Pharmaceuticals shares in Q2 2022, an estimated $77K.
Skaana Management first reported a position in Inovio Pharmaceuticals in Q4 2021 and held it in 2 quarters.
Skaana Management's Inovio Pharmaceuticals position peaked at $1.14M in Q4 2021.
184 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2022.

Based on Skaana Management's 13F filing for Q2 2022, filed 11 Aug 2022.